Last reviewed · How we verify

GZR18 — Competitive Intelligence Brief

GZR18 (GZR18) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Long-acting basal insulin analog. Area: Diabetes.

phase 3 Long-acting basal insulin analog Insulin receptor Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

GZR18 (GZR18) — Gan & Lee Pharmaceuticals.. GZR18 is a long-acting basal insulin analog designed to provide sustained glucose control in diabetes.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
GZR18 TARGET GZR18 Gan & Lee Pharmaceuticals. phase 3 Long-acting basal insulin analog Insulin receptor
Tresiba INSULIN DEGLUDEC Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2015-01-01
Levemir INSULIN DETEMIR Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2005-01-01
Apidra INSULIN GLULISINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2004-01-01
Novolog INSULIN ASPART Novo Nordisk marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Lantus INSULIN GLARGINE Sanofi marketed Insulin Analog [EPC] Insulin receptor 2000-01-01
Humalog INSULIN LISPRO Eli Lilly marketed Insulin Analog [EPC] Insulin receptor 1996-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Long-acting basal insulin analog class)

  1. Novo Nordisk A/S · 2 drugs in this class
  2. Institut de Recherches Cliniques de Montreal · 1 drug in this class
  3. Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
  4. Les Laboratoires des Médicaments Stériles · 1 drug in this class
  5. Merete Bechmann Christensen · 1 drug in this class
  6. Nanjing First Hospital, Nanjing Medical University · 1 drug in this class
  7. Sydney Children's Hospitals Network · 1 drug in this class
  8. The Cleveland Clinic · 1 drug in this class
  9. Gan & Lee Pharmaceuticals. · 1 drug in this class
  10. University of Split, School of Medicine · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). GZR18 — Competitive Intelligence Brief. https://druglandscape.com/ci/gzr18. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: